This Article Full Text Full Text (PDF) All Versions of this Article: 116/3/285    most recent CIRCULATIONAHA.107.689141v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Krankenberg, H. Articles by Zeller, T. Search for Related Content PubMed PubMed Citation Articles by Krankenberg, H. Articles by Zeller, T. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Angioplasty Related Collections Restenosis Related Article

(Circulation. 2007;116:285-292.)
© 2007 American Heart Association, Inc.

Interventional Cardiology

Nitinol Stent Implantation Versus Percutaneous Transluminal Angioplasty in Superficial Femoral Artery Lesions up to 10 cm in Length

The Femoral Artery Stenting Trial (FAST)

Hans Krankenberg, MD; Michael Schlüter, PhD; Hermann J. Steinkamp, MD; Karlheinz Bürgelin, MD; Dierk Scheinert, MD; Karl-Ludwig Schulte, MD; Erich Minar, MD; Patrick Peeters, MD; Marc Bosiers, MD; Gunnar Tepe, MD; Bernhard Reimers, MD; Felix Mahler, MD; Thilo Tübler, MD; Thomas Zeller, MD

From the Hamburg University Cardiovascular Center, Prof Mathey, Prof Schofer, & Partners, Hamburg, Germany (H.K., M.S., T.T.); DRK-Kliniken Berlin Westend, Institut für Klinische Radiologie, Berlin, Germany (H.J.S.); University of Leipzig Heart Center, Leipzig, Germany (D.S.); Vascular Center Berlin, Evangelisches Krankenhaus Königin Elisabeth Herzberge, Berlin, Germany (K.-L.S.); Department of Angiology, Vienna Medical University, Vienna, Austria (E.M.); Department of Cardiovascular and Thoracic Surgery, Imelda Hospital, Bonheiden, Belgium (P.P.); Department of Vascular Surgery, AZ Sint-Blasius, Dendermonde, Belgium (M.B.); Department of Diagnostic Radiology, University of Tübingen, Tübingen, Germany (G.T.); Department of Cardiology, Ospedale di Mirano, Mirano, Italy (B.R.); Inselspital, University of Bern, Bern, Switzerland (F.M.); and Department of Angiology, Herz-Zentrum Bad Krozingen, Bad Krozingen, Germany (K.B., T.Z.).

Correspondence to Hans Krankenberg, MD, Hamburg University Cardiovascular Center, Prof Mathey, Prof Schofer, & Partners, Wördemanns Weg 25-27, D-22527 Hamburg, Germany. E-mail krankenberg{at}herz-hh.de

Received January 9, 2007; accepted May 11, 2007.

Background— Endoluminal treatment of superficial femoral artery lesions is a matter of controversy. The present study was designed to investigate the impact of nitinol stenting of superficial femoral artery lesions with a maximum length of 10 cm on restenosis and clinical outcomes at 1 year.

Methods and Results— Two hundred forty-four patients (168 men; 66±9 years) with a single superficial femoral artery lesion and chronic limb ischemia were randomized to implantation of a single Bard Luminexx 3 stent (123 patients) or stand-alone percutaneous transluminal angioplasty (PTA) (121 patients). Mean lesion length was 45 mm. Technical success (residual stenosis <50% for PTA, <30% for stenting) was achieved in 96 patients assigned to PTA (79%) and 117 patients assigned to stenting (95%); 13 PTA group patients (11%) "crossed over" to stenting. At 1 year, the primary end point of ultrasound-assessed binary restenosis was reached in 39 of 101 PTA group patients (38.6%) and 32 of 101 stent group patients (31.7%; absolute treatment difference, –6.9%; 95% CI, –19.7% to 6.2%; P=0.377). Target lesion revascularization rates at 1 year were 18.3% and 14.9%, respectively (absolute treatment difference, –3.3%; 95% CI, –13.0% to 6.4%; P=0.595). No statistically significant difference between treatment groups was observed at 12 months in the improvement by at least 1 Rutherford category of peripheral arterial disease.

Conclusions— In the present study of patients with short superficial femoral artery lesions, the hypothesized absolute difference of 20% in binary restenosis at 1 year between the implantation of a single Luminexx nitinol stent and stand-alone PTA could not be demonstrated. A smaller difference requiring a larger trial might have been missed.

---

 

CLINICAL PERSPECTIVE

Related Article:

Issue Highlights
Circulation 2007 116: 231. [Extract] [Full Text]

This article has been cited by other articles:

				C. Kasapis and H. S. Gurm Routine stent implantation vs. percutaneous transluminal angioplasty in femoropopliteal artery disease: a meta-analysis of randomized controlled trials: reply Eur. Heart J., October 31, 2009; (2009) ehp467v1. [Full Text] [PDF]

				J. Ruef One-Year Follow-up After Implantation of the EverFlex Nitinol Stent in Long Lesions of the Superficial Femoral Artery Angiology, February 1, 2009; 60(1): 31 - 35. [Abstract] [PDF]

				C. Kasapis, P. K. Henke, S. J. Chetcuti, G. C. Koenig, J. E. Rectenwald, V. N. Krishnamurthy, P. M. Grossman, and H. S. Gurm Routine stent implantation vs. percutaneous transluminal angioplasty in femoropopliteal artery disease: a meta-analysis of randomized controlled trials Eur. Heart J., January 1, 2009; 30(1): 44 - 55. [Abstract] [Full Text] [PDF]

				S. R. Dixon, C. L. Grines, and W. W. O'Neill The year in interventional cardiology. J. Am. Coll. Cardiol., June 17, 2008; 51(24): 2355 - 2369. [Full Text] [PDF]

				E. L. Chaikof and J. Y. Wang Commentary on "Biological Treatment of Vein Grafts and Stents in Lower-Extremity Arterial Reconstruction" Perspectives in Vascular Surgery and Endovascular Therapy, September 1, 2007; 19(3): 298 - 299. [PDF]